Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
Status:
Completed
Trial end date:
2011-02-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the effect of a two-week pre-surgery treatment
with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid)
methyltransferase (MGMT) activity in patients with gliomas.